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Introduction
Cholesterol 7α-hydroxylase (cytochrome P450 7A1, CYP7A1) plays an important role in maintaining cholesterol homeostasis by catalyzing the rate-limiting step in bile acid biosynthesis from hepatic cholesterol (Myant and Mitropoulos, 1977; Jelinek et al., 1990; Redinger, 2003) . CYP7A1 is regulated mainly at the transcription level by various effectors such as diurnal rhythm, stress, xenobiotics, cholesterol, and bile acids, the direct end products of CYP7A1 (Yamagata et al., 2004) . Transcriptional regulation of CYP7A1 is achieved by interactions among various nuclear hormone receptors, including hepatocyte nuclear factor-4α (HNF-4α) (Cooper et al., 1997) , alpha(1)-fetoprotein transcription factor (FTF) (del Castillo-Olivares and Gil, 2000) , small heterodimer partner (SHP) (Goodwin et al., 2000; Lu et al., 2000) , and peroxisome proliferator activated receptor γ coactivator-1α (PGC-1α) (Shin et al., 2003; Ponugoti et al., 2007) .
Forkhead transcription factor O1 (FOXO1) mediates the important effects of insulin as a member of insulin signaling cascade (Barthel et al., 2005) in liver, pancreas, skeletal muscle, adipose tissue and hypothalamus. In hypothalamus, FOXO1 controls food intake by regulating the transcription of orexigenic (NPY and AgRP) and antiorexigenic (POMC) neutopeptides (Kim et al., 2006) . FOXO1 is exclusively expressed in β-cells in adult pancreas and involved in proliferation and differentiation of β-cell (Kitamura and Ido Kitamura, 2007) . In adipose tissue and skeletal muscle, FOXO1 prevents differentiations of preadipocytes and myoblast (Farmer, 2003; Kamei et al., 2004) . In liver, FOXO1 augments hepatic glucose production through transcription of gluconeogenic genes, PEPCK and G6Pase (Puigserver et al., 2003) , and suppresses glycolysis and lipogenesis by inhibiting expressions of glucokinase and SREBP-1c. FOXO1 also enhances the apoprotein apoC-III expression (Altomonte et al., 2004) , resulting in the increased plasma triglyceride levels. Thus, FOXO1 regulates multiple aspects of glucose and lipid metabolism in the liver. FOXO1 knockout mice are embryonic lethal due to incomplete vascular development (Furuyama et al., 2004) . Transgenic mice expressing FOXO1 showed the impaired insulin sensitivity, glucose intolerance, and the age-related muscle atropy, all of which lead to obesity and diabetes (Kamei et al., 2004; Zhang et al., 2006) . FOXO1 activity is regulated by PI3K/Akt-mediated phosphorylation (van der Horst and Burgering, 2007) . In response to insulin, PI3K phosphorylated Akt, and the phospho-Akt (pAkt) directly phosphorylates FOXO1 at three conserved residues (Thr24, Ser256, and Ser319). The phospho-FOXO1 (pFOXO1) is excluded from nucleus, and degraded by ubiquitin proteasome pathway in cytoplasm, which results in the suppression of target gene transcriptions. Therefore, mutations at phosphorylation sites of FOXO1 generate constitutively active form of FOXO1 (FOXO1-3A) which activates target gene expressions (Biggs et al., 1999; Tang et al., 1999) . FOXO1 is a nuclear transcription factor which interacts with insulin response elements (IREs), T(G/A)TTT(T/G) (G/T), in the promoter of target genes involved in cell cycle, apoptosis, oxidative-stress resistance, and metabolism (Barthel et al., 2005; Kitamura and Ido Kitamura, 2007; van der Horst and Burgering, 2007) . FOXO1 also regulates genes as a co-activator or co-repressor of many transcription factors.
We found eight and five putative IREs in the rat and human CYP7A1 promoters, respectively. There are several reports on differential regulation of mouse and human CYP7A1 (Chen et al., 2001; Goodwin et al., 2003; Kim et al., 2004) . In the present study, we investigated whether FOXO1 might participate in the regulation of rat CYP7A1 transcription to control cholesterol/bile acid metabolisms as well as glucose metabolism in liver, possibly linking the two major metabolic pathways. Using co-transfection assays, we found the FOXO1-dependent rat CYP7A1 transcription, which was suppressed by the insulin/ PI3K/Akt pathway and bile acids. Besides the inactivation of the signaling pathway, up-regulation of SHP by insulin may lead to the suppression of CYP7A1 like bile acids.
Results

FOXO1 is the positive regulator of the rat CYP7A1 transcription
The sequences of rat CYP7A1 promoter region (between -402 and +4 from transcriptional start or between -436 and -30 from translation start codon) are rich in A-T and contain 8 putative FOXO binding consensus sequences (IRE-likes) ( Figure 1A ). (B-D) . Induction of rat CYP7A1 promoter (rCYP7A1-luc) activity by FOXO1 and PGC-1α. HepG2 cells were transiently co-transfected with rCYP7A1-luc with or without increasing amounts of FOXO1, FOXO1-3A, or PGC-1α as indicated and harvested for luciferase assay. In D, 100 ng Foxo1 was co-transfected. Luciferase activities were expressed as a fold induction of the mock control. Values are mean ± SD of three independent assays of duplicates (n = 6). To test if FOXO1 induces rat CYP7A1 transcription, HepG2 cells were co-transfected with pCYP7A1-luc and various amounts of FOXO1. Figure 1B showed that FOXO1 increased the CYP7A1-luc activity in a dose-dependent manner. CYP7A1 activation by the constitutively active (dominant positive) form of FOXO1 (FOXO1-3A) was stronger than by the wild type FOXO1, which suggested that CYP7A1 promoter activity might depend on FOXO1 phosphorylation. A well-known co-activator PGC-1α exhibited the dose-dependent increase of CYP7A1-luc with or without 100 ng FOXO1 ( Figures 1C and 1D) . The results suggest that FOXO1 may modulate CYP7A1 transcriptional activity onto its promoter and PGC-1α co-regulates the CYP7A1 transcription.
Co-operative activation of rat CYP7A1 by FTF, HNF-4α and PGC-1α
Many nuclear receptors are involved in CYP7A1 transcriptional regulation. The transcriptional regulatory network of CYP7A1 is complex to clarify the interactions between nuclear receptors. This is partly because nuclear receptors differentially regulate rat and human CYP7A1 expression. Therefore, we confirmed the transcription activities of FTF (mouse homologue LRH-1, liver receptor homologue-1) and HNF-4α on rat CYP7A1-luc. As expected, FTF increased CYP7A1-luc in a dose-dependent manner and HNF-4α additionally increased the FTF-induced CYP7A1 ( Figure 2A ). PGC-1α did not co-activate FTF activity ( Figure 2B ), whereas it did strongly HNF-4α activity ( Figure 2C ) to the similar extend with FOXO1 ( Figure 1D ). When CYP7A1 is highly induced by FTF and HNF-4α, co-activation of PGC-1α was not as strong as in HNF-4α only ( Figure 2D ). The results suggest that a strong repressor may maintain the appropriate transcriptional level of CYP7A1 through controlling a positive regulator of FTF.
Strong repression of rat CYP7A1 by SHP in the presence of FTF
Bile acid mediates feedback repression of CYP7A1 by enhancing the expression of SHP (Lu et al., 2000) , since SHP hinders LRH-1 binding to CYP7A1 promoter by interacting directly with LRH-1, a mouse homologue of FTF (Goodwin et al., 2000) . It is not clear whether SHP interacts with FOXO1 or PGC-1α to control CYP7A1 transcription. Again, we performed co-transfection analyses using rat CYP7A1-luc and combinations of nuclear receptors. SHP reduced the CYP7A1-luc activity ( Figure 3A ). Here, it should be noted that 0.1 μg of SHP inhibited 50% of CYP7A1 transcription and 1 μg of SHP decreased only 60% of the activity. On the other hand, SHP clearly repressed the FOXO1-induced CYP7A1 transcription in a dose-dependent manner ( Figure 3B ). Similarly to LRH-1, the FTF-induced CYP7A1 activity was strongly suppressed by co-expression of SHP ( Figure 3C ). The inhibitory effects of SHP on FTF were stronger than on FOXO1 or HNF-4α ( Figure 3D ), implying that SHP might preferentially interact with FTF rather than FOXO1 or HNF-4α. Therefore, the presence of FTF makes the CYP7A1 transcription control sensitive to SHP. It is not clear why a low concentration of SHP stimulates CYP7A1 a little further in the presence of HNF-4α ( Figures 3D and 3F ). In the presence of FTF, however, 100 ng of SHP almost completely suppressed the CYP7A1 promoter activity despite of co-expressions of positive regulators, HNF-4α and PGC-1α ( Figure 3E ). Maximum amount (1 μg) of PGC-1α co-expression did not restore the SHP-mediated repression to the initial level without SHP. In contrast, 100 ng of SHP was enough to abolish the CYP7A1 promoter activity induced by FTF, HNF-4α and PGC-1α ( Figure  3F ). To achieve the SHP-mediated repression in the presence of PGC-1α, an approximate molar ra- tio of SHP to PGC-1α was 1:40, which means only 1/40 of SHP is required to abolish the PGC-1α-mediated co-activation, implying that SHP may be the most critical control factor for CYP7A1 transcription.
FOXO1 is a mild negative regulator of the human CYP7A1 transcription
To compare the effects of FOXO1 on human CYP7A1 promoter, we have constructed the human CYP promoter (-326 to +104)-luciferase plasmids by PCR and performed the similar co-transfection assays ( Figure 4A ). Although the human CYP7A1 promoter contains three putative, but not clearly conserved, IREs, FOXO1 dose-dependently decreased the human CYP7A1 promoter activity in HepG2 cells ( Figure 4B ). Here, we have to note that rat CYP7A1 promoter was 10-fold more sensitive to FOXO1 than human CYP7A1 to confer the activity. Deletion of IRE-1 (ΔIRE-1) had no effects on hCYP7A1-luc activity ( Figure 4C ). Deletions of IRE-2 or IRE-3 (ΔIRE-2 or ΔIRE-3) enhanced hCYP7A1-luc but FOXO1-mediated repression was not abolished. Thus, IRE-1 is not functional and both IRE-2 and IRE-3 may be the binding sites of FOXO1. ChIP analysis of HepG2 cells revealed the direct binding of FOXO1 to human CYP7A1 promoter ( Figure 4D ). FOXO1-3A overexpression using adenovirus enhanced FOXO1 binding to human CYP7A1 promoter, but it did not increase PGC-1α binding to the promoter. Insulin treatment for 30 min increased phosphorylation and degradation of FOXO1, but did not alter the PGC-1α expression ( Figure 4E ).
CYP7A1 expression was down-regulated by insulin in vitro and in vivo
Diabetic patients and experimental diabetic animals showed the enhanced levels of bile acids pool and excretion. Insulin normalized the elevated bile acids in diabetes and reduced the CYP7A1 transcription in rat primary hepatocytes (Twisk et al., 1995) . Reflecting insulin-activated PI3K-Akt protein kinase cascade and FOXO1 phosphorylation, we expected that insulin would repress CYP7A1 expression via inactivation of FOXO1. The insulin treatment down-regulated the mRNA levels of CYP7A1 in HepG2 cells ( Figure 5 ) and murine liver (Figure 6 ). Insulin decreased hCYP7A1 mRNA within 4 h, while it rapidly increased hSHP mRNA up to 17-fold in 2 h in HepG2 cells, which were determined by semi-qRT-PCR ( Figure 5B ) or real-time PCR ( Figure 5C ). In order to determine the effects of insulin on mRNAs of rodent CYP7A1 and SHP in vivo, we intraperitoneally injected insulin into C57BL/6 mice (n = 3) and isolated livers after 2 h. Insulin also down-regulated the mCYP7A1 mRNA and enhanced mSHP mRNA in mouse liver (Figure 6 ). The results suggest that the rapid increase of SHP may be involved in the insulin-mediated repression of CYP7A1 transcription. Cross-linked chromatin solution was immunoprecipitated with anti-FOXO1. Normal mouse IgG or anti-RNA polymerase II (RNA pol II) were utilized as negative and positive controls, respectively. Ten percent of the soluble chromatin used in the reaction was used as inputs. Precipitated DNA was analyzed by PCR using primer sets for the rat CYP7A1 promoter regions. FOXO bound to the promoter was quantified and normalized by RNA pol II. (D) FOXO1 phosphorylation-independent inhibition of rCYP7A1 by bile acids. HepG2 cells transfected with rCYP7A1-luc, FOXO1 (or FOXO1-3A) were treated with CDCA (0, 25, 50, 100 μM) in SFM for 24 h. Luciferase activities were expressed as a fold induction of the mock control (n = 6, **P ＜ 0.01 vs. PBS).
Rat CYP7A1 promoter activity was regulated by insulin-PI3K-Akt-FOXO1 signaling pathway
To determine if FOXO1 phosphorylation by insulin is involved in rat CYP7A1 transcriptional activity, constitutively active FOXO1, FOXO1-3A, was co-transfected with rCYP7A1-luc. Figure 7A shows that FOXO1 phosphorylation also contributes to the insulin-mediated decrease of rat CYP7A1 because FOXO1-3A transfection-induced CYP7A1 was not affected by insulin differently from the FOXO1-treated. FOXO1 activity is negatively regulated by Akt and PI3K. PI3K consists of p85 regulatory and p110 catalytic subunits. The labile p110 is stabilized by p85. As expected, the FOXO1-induced rat CYP7A1 was inactivated by Akt or PI3K-p110 (dominant positives) and further activated by PI3K-Δp85 (dominant negative) co-transfection, supporting that the effects of FOXO1 on rat CYP7A1 might be under the control of PI3K and Akt ( Figure 7B ). Effects of PI3K-Akt were abolished in the FOXO1-3A transfected cells. ChIP analysis of rat hepatoma H4IIE cells demonstrated that FOXO1 was bound directly to CYP7A1 promoter and insulin displaced its binding when FOXO1 was overexpressed ( Figure  7C ). Co-transfection of SHP also reduced FOXO1 bound to the promoter, suggesting that augmentation of SHP expression by insulin suppressed the FOXO1-dependent CYP7A1 expression. CDCA is a hydrophobic primary bile acid which activates SHP transcription (Goodwin et al., 2000) . CDCA also decreased rat CYP7A1 promoter activity of the FOXO1-or the FOXO1-3A-transfected cells in a dose-dependent manner ( Figure 7D ). Hence, both insulin and CDCA may down-regulate the FOXO1-dependent rat CYP7A1 transactivation through SHP/FOXO1-dependent pathway.
Discussion
In the present study, we demonstrated that FOXO1 was a transcriptional activator of rat CYP7A1 under the tight control of insulin-PI3K-Akt signaling cascade. Insulin and bile acid suppress rat CYP7A1 transcription via both FOXO1 inactivation and SHP induction. PGC-1α and SHP were co-regulators of rat CYP7A1 transcription. On the other hand, FOXO1 was not, but SHP was a critical modulator of human CYP7A1 transcription in response to insulin.
The transcriptional regulation of CYP7A1 is complex to understand. The confusion had been caused by the differential regulation of bile acid and cholesterol metabolisms between rodents and humans. First, FTF stimulated the rat CYP7A1 transcription (del Castillo-Olivares and Gil, 2000; Goodwin et al., 2000; Lu et al., 2000) , but it repressed the human CYP7A1 activity (Chen et al., 2001) . Second, LXRα stimulated the rat CYP7A1, but not human CYP7A1 promoter activity because human CYP7A1 promoter lacks LXR elements (Chen et al., 2002; Goodwin et al., 2003) . Here, we added another transcription factor, FOXO1, showing differences in CYP7A1 regulation between rodent and human.
There are several contradictory reports on the CYP7A1 gene regulation by insulin. It has been reported that insulin inhibits the transcription of mouse CYP7A1 because the insulin-induced SREBP-1c blocks the functional interaction between HNF-4α and PGC-1α as a non-DNA binding inhibitor (Ponugoti et al., 2007) . Furthermore, microarray analysis of liver from the transgenic mice overexpressing FOXO1 revealed 2-fold increase of CYP7A1 and 40% decrease of SREBP-1c (Zhang et al., 2006) . Feeding (physiological increase of insulin) decreased CYP7A1 mRNA by 90% compared to the fasting state in mice. The fasting induction of CYP7A1 was blunted in liver-specific FOXO1 knock-out mice (Shin and Osborne, 2009 ). In contrast, insulin at physiological concentrations showed dual effects on human CYP7A1 gene expression; a rapid stimulation of human CYP7A1 through FOXO1 inactivation and a late repression of CYP7A1 mediated by prolonged insulin exposure-induced SREBP-1c (Li et al., 2006) . It has been reported that FOXO1 is a strong repressor in human CYP7A1 transcription because siRNA knockdown of FOXO1 induced 6-fold CYP7A1 mRNA and dominant positive FOXO1 inhibited it in human primary culture (Li et al., 2009) .
It is confusing because insulin treatment decreases both human and rodent CYP7A1 mRNA expressions despite of the opposite role of FOXO1 in two species. Here, we have to note that insulin rapidly and strongly induced SHP mRNA in both human cells and mice. SHP is an interesting and powerful negative regulator of various nuclear receptors in vivo and in vitro because it lacks the DNA binding domain (Lee et al., 2010) . SHP directly binds to FOXO1 or HNF-4α to dissociate them from promoters of G6Pase or PEPCK, respectively (Yamagata et al., 2004) . SHP also suppressed the FTF-mediated transactivation in the strongest manner. Therefore, it is possible that insulin-induced SHP hinders the binding of FOXO1, HNF-4α, and FTF to rat and human CYP1A1 promoters by interacting with them, resulting in suppression of transcription. It was confirmed that SHP overexpression dissociated FOXO1 from rat CYP7A1 promoter ( Figure 6C) . Alternatively, the transcriptional regulation of human CYP7A1 by insulin may be achieved mainly by transcription factor other than FOXO1, like SREBP-1c differently from rodent CYP7A1. Thus, SREBP1c would link the insulin action to lipid/bile acid homeostasis in human. In conclusion, the results suggest that a prolonged exposure of insulin in hyperinsulinemic insulin resistance or diabetic status represses CYP7A1 transcription and bile acid biosynthesis through SHP induction and FOXO1 inactivation, leading to impairment of the cholesterol/bile acid metabolisms. The insulin-mediated regulatory network of rat CYP7A1 expression is summarized in Figure 8 . Further study on the relation among FOXO1, SHP, and CYP7A1 using clinical samples may enhance the understanding of pathogenesis of cardiovascular complications in diabetic patients. Again, our study draws an attention to rodent study when we investigate the molecular mechanism of insulin resistance and the effects of therapeutic interventions on bile acid or cholesterol metabolism.
Methods
Cell culture and transient transfection
HepG2 cells (ATCC, HB-8085) were cultured in Minimum Essential Medium (MEM) supplemented with 10% fetal bovine serum (FBS) and 100 μg/ml penicillin and 100 μg/ml streptomycin at 37 o C/5% CO2. For transient transfections, the cells (4 × 10 5 cells/well) in 6-well plates were transfected with the indicated plasmid(s) and expression vector of β-galactosidase (pcDNA3.1/LacZ) by calcium phosphate co-precipitation method (Jeong et al., 2009) . The total amounts of expression vectors were kept constant by adding the pcDNA3.1/HisC expression vector to transfection. After 36 h incubation in MEM containing 10% FBS, the cells were harvested and luciferase activity was measured using luciferase assay kit (Promega, Madison, WI) and luminometer (Berthold, German). The transfection efficiencies were normalized by the β-galactosidase activity.
To determine the effects of insulin or chenodeoxycholic acid (CDCA), HepG2 cells were cultured in serum free MEM for 16 h and treated with 100 nM insulin for 2 h, 4 h or 16 h or with 0-100 μM CDCA for 24 h. The cells were harvested for western blot or semi-quantitative RT-PCR analysis.
Animals
C57BL6 mice (9 weeks old, n = 3) were injected intraperitoneally (1 U/kg in 100 μl). After 2 h, hepatic total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA), and the CYP7A1 mRNA was determined by semi-quantitative and real time qRT-PCR using mouse specific primers.
Plasmids
FOXO1 and constitutively active FOXO1 (FOXO1-3A) mammalian expression vectors were provided by Dr. Guan K.L. (Michigan University) (Kim et al., 2006) . Rat CYP7A1 promoter (-402 to +4 bp)-luciferase construct (pCYP7A1-luc), HNF-4α, and FTF expression vectors were obtained from Dr. Choi H.S. (Chonnam University, Korea). Human CYP7A1 promoter (-326 to +105 from transcriptional start +1) were amplified by PCR and cloned between Kpn I and Hind III of pGL3-basic and its sequences were verified (Figure 4) . Three deletion mutants (ΔIRE-1, ΔIRE-2, ΔIRE-3) that lacks each putative FOXO1 binding site were generated using oligonucleotide-directed mutagenesis and a two-step PCR procedures as described (Jeong et al., 2009) . The primer sequences for two-step PCR are following: hCYP7A1 promoter (5'-cgg ggt acc ttt atg tat tta tta gct at-3' and 5'-ccc aag ctt ctg cta tag caa tcc ccc aa-3'), ΔIRE-1 (5'-taaacaggtt acacatacca-3' and 5'-tggtatgtgt aacctgttta-3'), ΔIRE-2 (5'-aatggctaat tgtcaaccaa-3' and 5'-ttggttgaca attagccatt-3'), ΔIRE-3 (5'-agcttgagtc agtggcatcc-3' and ggatgccact gactcaagct-3'). Mammalian expression plasmids of Akt, PI3K p110, PI3K Δp85 were generously provided by Drs. Park HS (University of Seoul, Korea) and Ha JH (Kyung Hee University, Korea).
Chromatin immunoprecipitation (ChIP)
For rat CYP7A1 promoter binding, rat hepatoma H4IIE cells in 100 mm plate were transfected with 10 μg FOXO1 and/or 2.5 μg SHP using Superfect (Qiagen, Hilden, Germany). After 48 h, the transfected cells were treated with 100 nM insulin for 1 h. For human CYP7A1 promoter binding, HepG2 cells were infected 14 h after plating with adenoviruses expressing either LacZ (Ad-LacZ) or dominant positive FOXO1-3A (Ad-FOXO1) at a multiplicity of infection (moi) of 50 (Kim et al., 2006) . At 4 h after infection, fresh growth medium was added and incubated for 36 h. ChIP assay was performed using the transfected or infected cells. Briefly, the cells were subjected to formaldehyde cross-linking for 15 min. The cross-linked protein-DNA complex in the soluble chromatin, which was prepared by sonication, was immunoprecipitated with anti-FOXO1, or anti-PGC-1α (Santa Cruz Biotechnology, Santa Cruz, CA). IgG was used as a negative control. Anti-acetyl histone 3 (Ac-H3, Santa Cruz, CA) or anti-RNA polymerase II (RNA pol II, Millipore, MA) antibodies was used as a positive control. Ten percent of the soluble chromatin used in the reaction was used as inputs. The precipitated DNA fragments were analyzed by 38-40 cycles of PCR using primers directed against human CYP7A1 promoter (forward 5'-tat gcc cat ctt aaa cag g-3' and reverse 5'-atc tag gcc aaa atc tct g-3') or rat CYP7A1 promoter (forward 5'-gct gtg gct tcc tgg tag atg-3' and reverse 5'-ccg aaa cag tgg gtc tga cta g-3').
Semi-quantitative and real time RT-PCR
Total RNA was prepared from cultured cells or livers by Trizol (Invitrogen). Semi-quantitative RT-PCR (semi-qRT-PCR) was performed to check primer dimer formation. RT-PCR products were visualized on 1.5% agarose gel and quantified by densitometry. Real time RT-PCR for CYP7A1 and SHP was performed using SYBR green dye on Light Cycler1.5 (Roche, Basel, Switzerland) with SYBR Ⓡ Premix Ex Taq TM (TaKaRa, Otsushiga, Japan) at 95 o C for 10 sec, followed by 40 cycles of 95 o C for 5 s and 60 o C for 34 s according to the manufacturer's protocol. Measurement was performed in duplicate for each sample. Primer sequences, product size, annealing temperature and the number of cycles for semi-qRT-PCR were following: human CYP7A1 (101 bp, 61 o C, 25 cycles), 5'-cca tta ggt gtt gtg cca cg-3' and 5'-cat cca tcg ggt caa tgc tt-3'; mouse CYP7A1 (102 bp, 65 o C, 26 cycles), 5'-cca ggg aga tgc tct gtg ttc-3' and 5'-acc cag aca gcg ctc ttt gat -3'; human SHP (107 bp, 61 o C, 25 cycles), 5'-gac ttc ctt ggt ttg gac aca-3' and 5'-gct ttc att ctc atc cca aga-3'; mouse SHP (101 bp, 65 o C, 26 cycles), 5'-acg atc ctc ttc aac cca gat g-3' and 5'-ggc tcc aag act tca cac agt-3'; human and mouse 18S rRNA (102 bp, 60 o C, 26 cycles), 5'-gag cga aag cat ttg cca ag-3' and 5'-ggc atc gtt tat ggt cgg aa-3'.
Statistical analysis
Student's t-tests were performed using Instat or Prism (GraphPad Software, San Diego, CA) with significance set at P ＜ 0.05. Data represent mean ± standard deviation (SD) for experiments repeated 3-6 times on independent occasions.
